PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan

Podobne knjige/članki

• PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
  od: Sato, T, et al.
  Izdano: (2013)
• PReS-FINAL-2172: Efficacy of corticosteroids and intravenous cyclophosphamide for patients with juvenile systemic sclerosis
  od: Kikuchi, M, et al.
  Izdano: (2013)
• PReS-FINAL-2189: Tocillizumab for patients with takayasu arteritis in childhood refractory to conventional therapy
  od: Yamazaki, K, et al.
  Izdano: (2013)
• Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
  od: Miyamae, Takako, et al.
  Izdano: (2011)
• PReS-FINAL-2041: Macrophage activation syndrome in the children with systemic juvenile idiopathic arthritis during the course of tocilizumab
  od: Alekseeva, E, et al.
  Izdano: (2013)